RT Journal Article
T1 SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
A1 Piñana, Jose Luis
A1 Lopez-Corral, Lucia
A1 Martino, Rodrigo
A1 Montoro, Juan
A1 Vazquez, Lourdes
A1 Perez, Ariadna
A1 Martin-Martin, Gabriel
A1 Facal-Malvar, Ana
A1 Ferrer, Elena
A1 Pascual, María-Jesus
A1 Sanz-Linares, Gabriela
A1 Gago, Beatriz
A1 Sanchez-Salinas, Andres
A1 Villalon, Lucia
A1 Conesa-Garcia, Venancio
A1 Olave, Maria T
A1 Lopez-Jimenez, Javier
A1 Marcos-Corrales, Sara
A1 Garcia-Blazquez, Marta
A1 Garcia-Gutierrez, Valentin
A1 Hernandez-Rivas, Jose Angel
A1 Saus, Ana
A1 Espigado, Ildefonso
A1 Alonso, Carmen
A1 Hernani, Rafael
A1 Solano, Carlos
A1 Ferrer-Lores, Blanca
A1 Guerreiro, Manuel
A1 Ruiz-Garcia, Montserrat
A1 Muñoz-Bellido, Juan Luis
A1 Navarro, David
A1 Cedillo, Angel
A1 Sureda, Anna
K1 Antibodies, Viral
K1 COVID-19
K1 COVID-19 Vaccines
K1 Hematopoietic Stem Cell Transplantation
AB This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia< 1 109/ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16–0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27–0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15–0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR0.09, 95% CI 0.02–0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02–0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring.
PB Wiley Periodicals LLC
YR 2021
FD 2021-12-08
LK http://hdl.handle.net/10668/19952
UL http://hdl.handle.net/10668/19952
LA en
NO Piñana JL, López-Corral L, Martino R, Montoro J, Vazquez L, Pérez A, et al.  SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022 Jan 1;97(1):30-42
DS RISalud
RD Jul 6, 2025